A safe and effective non-surgical and reversible procedure for weight loss

Informazioni relative al progetto

GDS

ID dell’accordo di sovvenzione: 814638

DOI

10.3030/814638

Progetto chiuso

Data della firma CE 28 Maggio 2018

Data di avvio 1 Giugno 2018

Data di completamento 30 Settembre 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

ALLEVETIX MEDICAL LTD
Israel

Periodic Reporting for period 1 - GDS (A safe and effective non-surgical and reversible procedure for weight loss)

Periodo di rendicontazione: 2018-06-01 al 2018-09-30

Sintesi del contesto e degli obiettivi generali del progetto

Allevetix Medical Ltd is an Israeli biotech company founded in 2014 that is working towards bringing to market the new standard in T2DM and weight loss treatments. The team’s vision is to address the emerging obesity and diabetes problems with a simple, effective, reversible and affordable solution, addressing the needs of millions. The NOBIX System.
The key objectives of the development are miniaturization of the delivery system; improvement of the anticorrosion surface treatment; optimization of the locking mechanism of the anchor and improvement of the sleeve; safety and efficacy validation on T2DM patients; CE mark and ISO 13485 certification.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Throughout the duration of the project, Allevetix defined the preliminary updates in the miniaturisation and optimisation of the device, reviewed its development plan, supply chain, and scouted for third parties to support in the development stage and the distribution channels. The market segments and opportunities have also been evaluated, defining the TAM and SAM. A commercialisation strategy has been established. The Phase 1 feasibility assessment has determined that a development plan for the NOBIX System is technically and commercially viable, and that further engineering, manufacturing and commercialisation plan should be pursued. The SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

There are about 60 million people with diabetes in Europe, or about 10.3% of men and 9.6% of women aged 25 years and over. This number is expected to increase up to 71.1 million by 2040. T2DM accounts for at least 90% of all cases of diabetes, and it is often associated with overweight or obesity. Obesity has become a serious global health problem: nearly 15% of people over 18 years are obese (11% of men and 15% of women) according to WHO standards. Obesity has a far-ranging negative effect on health, leading to diabetes, coronary heart disease, and several types of cancers.
The NOBIX System is a non-surgical reversible solution for hormonal balance and weight-loss of patients with T2DM, with zero side effects, immediate recovery and no need for a prolongued hospitalization.

nobix-system.png